Article Review: Nancy McWilliams, Psychoanalytic Diagnosis. Chapter 3: Developmental Levels of Personality Organization

 

Psychologists work with complex diagnostic and treatment issues on a daily basis. Current standards of care (and reimbursement) have guided diagnosis and treatment to seem focused on DSM-5 categories and ICD-10 codes. Clinicians I have interacted with seem to appreciate the aspects of continuum versus strictly categorical diagnoses added to DSM-5. This may open avenues into helping psychologists better describe, understand and treat their patients with compassion.

 

A continuum model of personality organization is outlined in chapter 3 of Nancy McWillam’s book, Psychoanalytic Diagnosis. This model has important implications in the work clinicians do with patients regardless of their chosen theoretical orientation. The psychodynamic concepts in this particular chapter apply to any overriding theoretical orientation just as the concept of transference does. In the middle of the 20th century and beyond, many analysts followed in the tradition of Freud in differentiating psychopathological conditions as either neurotic or psychotic. Neurotics were described as having some insight into their difficulties of which, a source of reality based stress was likely being managed poorly. Conversely, psychotics who were having psychological difficulties experienced distress based on misinterpretations of reality. At the same time other clinicians began to question these discrete categories because they noticed patients who seemed to fall on a borderline between neurosis and psychosis. It is a crucial point to understand that this concept is NOT describing Borderline Personality Disorder. We all have a unique personality that has developed for a variety of biological and psychological reasons. The model described in McWilliams’s book and by many other modern psychodynamic theorists, organizes personality in a thermometer like fashion with three overall categories: Neurotic, Borderline and Psychotic. Levels of personality organization tend to lend themselves to the idea of fixation in a particular developmental stage.

 

Neurotic Personality Organization
When a patient with Neurotic Personality Organization (NPO) presents to psychotherapy, it is more likely that they see their distress as ego dystonic or ego alien. NPO typically relies on repression as a defense mechanism as opposed to more primitive defenses such as splitting, or projective identification. If you ask a neurotically organized patient to tell you about themselves, they can describe a person who has an integrated sense of identity on some level. They can tell you enduring traits about themselves and have some insight into what parts of themselves have been more constant over time. It requires a severe biological or traumatic event for Neurotically Organized personalities to lose touch with reality. Schizophrenia as well as any Axis I disorder can exist in a neurotically organized individual. Neurotically organized individuals with psychotic disorders will be able to identify psychotic symptoms as not reality based and quickly access mental health services as a result. They tend to be individuals who will demonstrate a stronger recovery from psychosis due to remaining on prescribed medications, being able to identify stressful triggers, and most important reality testing remains intact even when the individual begins to experience symptoms. The patient knows they are sick and seeks help long before psychiatric hospitalization occurs.

 

Borderline Personality Organization
Borderline Personality Organization (again I cannot stress enough this is NOT the personality disorder), relies on a less developed defensive repertoire. Splitting occurs frequently at this general borderline personality organization (BPO) as well as with borderline personality disorders. Black and white thinking can be a part of those organized at this level. There are only good and bad, “my” way or the wrong way. If a BPO is asked to describe who they are the description may seem to vacillate based on the situation they are in. Their own sense of identity is not formed so it is more likely to be shaped as a result of the current relationship or environmental situation. Those with BPO are more prone to “micropsychotic” dips in times of stress. One diagnostic consideration this can be particularly helpful with is major depression. A depressed NPO will likely be able to identify stressors and respond to psychotherapy and medication in an expected manner. A depressed BPO is likely to have psychotic features. The patient is less likely to be able to explain what preceded the depression and much less likely to identify any time in their life they were not depressed. They are more likely to see any pathology as ego syntonic and be brought in for treatment by family members or others. Depressed BPO patients have great difficulty identifying a gray area between depressed and non-depressed states. They may describe themselves as “bipolar” when the actual problem is their inability to identify and label affect. Patients who report they have been diagnosed as bipolar but do not respond to “any” medications should raise some suspicion for this particular organizational level. BPO is unstable and ever changing which can give the impression of a bipolar element. Those functioning at this level may have times of calmer more successful neurotic level functioning coupled with dips into psychotic level function.

 

Psychotic Personality Organization
Like the other organizational levels this is not a psychotic “disorder.” Psychotically Organized Personalities are less likely to respond to standard treatment and more difficult to build rapport with. They often will not know how to begin describing themselves or any personality traits they have. Psychotic level individuals have lacking insight into their difficulties. If they have a psychotic disorder they may even seem at times to be unaware of it. They are not distressed by what others from the outside may conceptualize as distress. It is rare for this personality organization to be able to assess reality. This is the patient that may seem to make one bad decision after another based on a fact pattern others cannot identify. Psychotically organized patients are more likely to use schizoid retreat as a defense. They isolate from others and engage in an internal fantasy world that becomes difficult for them to differentiate from reality. This inevitable leads to interpersonal difficulties and more frequent interaction with law enforcement. A depressed psychotically organized patient is more likely to act out violently and see this as a viable solution to their discomfort. This patient will be disorganized and unable to identify why they are depressed or if they ever have been before. Some have learned to state they “always” have been depressed in some effort at interacting with treating clinicians. Further evaluation may identify few things that make sense in the patient’s behavior. It is important to gain an understanding of what it is that this individual (not the clinician) describes as reality and start working from that point.

 

Understanding
When treating patients many clinicians identify that not all depressed patients are alike. Why it is some seem to have insight and respond to treatment while others seem much more difficult? Identifying a patient’s personality organization can help clinicians in a variety of ways. It is less difficult to understand why a psychotically organized depressed patient will need a longer length of treatment and repeated treatment exposures. Understanding the personality context of a disorder may help decrease the clinician’s frustrations when treatment seems more difficult. The patient can be saved some degree of distress when they are aware of what their treatment may look like. The patient who is at a psychotic level of organization will need treatment patiently described over and over to understand the realities of treatment. Lapses in treatment make more sense when the clinician understands that they may be a result of the patient’s organizational level.

 

Reference
McWilliams, N. (1994) Psychoanalytic Diagnosis. Guilford Press, New York, NY.

 

Rain Blohm, MS
WKPIC Doctoral Intern

 

Friday Factoids: Where Do the 2016 Presidential Candidates Stand on Mental Health Issues?

 

In an election often dominated by worries about the economy and national security, mental health gets comparatively little exposure as a serious issue on the presidential campaign trail. In fact, during my search for information it was difficult to find clear and concise information about the candidates’ stance on mental health issues in America. During this election season, the issue of mental health services has been brought up most frequently when candidates have discussed mass shootings. Candidates on both sides of the aisle have stressed the need to prevent mentally ill people from acquiring guns. Democrats have advocated for gun control and Republicans argued that the lack of treatment for mental health issues should be blamed for mass shootings rather than the gun industry.

 

The heroin epidemic has provided an opportunity for candidates to link drug addiction and mental health, with candidates like Bernie Sanders arguing that the nation’s prison system must stop being used as a substitute for treatment. In addition, mental health is also commonly mentioned in regards to the Department of Veterans Affairs, with many candidates promising to reform the agency and give veterans access to proper mental health care. It is even rarer for candidates to mention mental health as its own issue, one that is not prompted by a national crisis or by a question from an audience member.

 

Out of all the 2016 candidates, Hillary Clinton and John Kasich are perhaps the most vocal advocates for mental health care. Clinton has called for mental health to be treated with parity to physical health issues. During the run-up to the Iowa caucus, Clinton frequently criticized the state’s Republican governor, Terry Branstad, for closing two of the state’s four mental hospitals. Kasich, who is often attacked by conservatives for expanding Medicaid in his home state of Ohio, has argued that the move helped treat the mentally ill. Bernie Sanders occasionally speaks about mental health as a part of his health care plan, and has called for a “mental health revolution,” usually in regards to making sure people are treated in light of the national conversation on mental health and guns.

 

Marco Rubio has talked about the stigma surrounding mental health issues when asked about it by voters. Some candidates have taken a different approach and have joked about the issue. Ted Cruz has said multiple times that he has “a lot of experience with mental health” issues because he’s dealt with Congress. One day after a man shot two journalists on live television Donald Trump said he is opposed to tightening gun laws in the U.S. but is in favor of addressing mental health to prevent shootings. Trump did not offer specific solutions to addressing the mental health problem, but said there are “so many things that can be done.”

 

When candidates do talk about mental health, what they say falls very clearly along party lines. Republican candidates who do address the issue tend to do so in the context of veterans affairs or to recommend institutionalizing certain mentally ill people rather than focusing on gun control. Democratic candidates who bring up mental health tend to do so in the context of reducing the flow in the prison pipeline and addressing substance use disorders. In other words and not surprisingly, mental health gets a mention where it seems to be politically expedient.

 

For more information, you can view each candidate’s political website.

 

References:
Willingham, E. (2015, September 6).What does your 2016 Presidential Candidate Say about Mental Health? Forbes. Retrieved from http://www.forbes.com/sites/emilywillingham/2015/09/06/what-does-your-2016-presidential-candidate-say-about-mental-health/#6ccc3de6884d

 

Witkin, R. (2016, February 24)Where the 2016 Candidates Stand on Mental Health Issues. NBCNews. Retrieved from http://www.nbcnews.com/politics/first-read/where-2016-candidates-stand-mental-health-issues-n524826

 

Jonathan Torres, M.S.
WKPIC Doctoral Intern

 

Friday Factoid Catch-up: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder

 

A drug often known as “Ecstasy” or “Molly,” has for decades been used as a party drug in clubs and for all-night raves. But lately, ±3, 4-methylenedioxymethamphetamine (MDMD) is also being used in very different settings and for a very different purpose. Pharmacologically, MDMA acts as a serotonin-norepinephrine-dopamine releasing agent and reuptake inhibitor. Basically, MDMA massively increases the release of serotonin, dopamine, and oxytocin. Respectively, these chemicals in the brain help you feel relaxed and calm, help you stay alert, and help you bond with people and be more trusting. Increased feelings of trust and compassion towards others would allow people to process their trauma, which could make an ideal adjunct to psychotherapy for PTSD.

 

The Food and Drug Administration (FDA) has approved phase two clinical studies of the treatment, and they are now underway in four separate locations in South Carolina, Colorado, Canada, and Israel. Results so far have been promising. Preliminary studies have shown that MDMA in conjunction with psychotherapy can help people overcome PTSD and possibly other disorders as well. MDMA is not the same as “Ecstasy” or “Molly.” Substances sold on the street under these names may contain MDMA, but frequently also contain unknown and/or dangerous adulterants. In laboratory studies, pure MDMA has been proven sufficiently safe for human consumption when taken a limited number of times in moderate doses. In MDMA-assisted psychotherapy, MDMA is only administered a few times, unlike most medications for mental illnesses which are often taken daily for years, and sometimes over the course of a lifetime.

 

Recent test results have shown 83 percent of the subjects receiving MDMA-assisted psychotherapy in a pilot study no longer met the criteria for PTSD, and every patient who received a placebo and then went on to receive MDMA-assisted psychotherapy experienced significant and lasting improvements. Long-term follow-up of patients who received MDMA-assisted psychotherapy revealed that overall benefits were maintained an average of 3.8 years later. These results indicate a promising future for MDMA-assisted psychotherapy for PTSD and lay the groundwork for continued research into the safest and most effective ways to administer the treatment.

 

The Multidisciplinary Association for Psychedelic Studies (MAPS) is undertaking a roughly $20 million plan to make MDMA into a FDA approved prescription medicine by 2021, and is currently the only organization in the world funding clinical trials of MDMA-assisted psychotherapy. For-profit pharmaceutical companies are not interested in developing MDMA into a medicine because the patent for MDMA has expired. Data from Phase 2 studies will be used to plan Phase 3of MAPS’ drug development program. MAPS will work with the FDA to agree on a design for Phase 3 studies and submit the findings to the FDA in a New Drug Application (NDA) to approve MDMA-assisted psychotherapy as a prescription treatment for PTSD. Phase 3 of the development program will involve scores of therapists and hundreds of subjects in multiple countries and large multi-center trials. The challenge is no longer convincing regulatory agencies of the value of this research, but finding the financial resources for conducting the Phase 3 studies required to make MDMA-assisted psychotherapy a legally available treatment for those who need it most.

 

References:
Mithoefer, M.C., Wagner, M.T., Mithoefer, A.T., Jerome, L., & Doblin, R. (2011). The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Journal of Psychopharmacology, 25(4), 439-452.

 

Mithoefer, M.C., Wagner, M.T., Mithoefer, A.T., Jerome, L., Martin, S.F., Yazar-Klosinski, B.,…Doblin, R. (2012). Durability of improvement in posttraumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. Journal of Psychopharmacology, 0 (0), 1-12. DOI: 10.1177/0269881112456611

 

Oehen, P., Traber, R., Widmer, V., & Schnyder, U. (2012). A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)- assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). Journal of Psychopharmacology, 0, 1-13. DOI: 10.1177/0269881112464827

 

Jonathan Torres, M.S.
WKPIC Doctoral Intern

 

Friday Factoid: U.S. Preventative Services Task Force (USPSTF) Recommends Depression Screening for Older Adolescents

Counseling

National data suggest that up to 8 percent of U.S. adolescents experience an episode of major depression in a given year. Children and adolescents with Major Depressive Disorder (MDD) typically have functional impairments in their performance at school or work, as well as in their interactions with their families and peers. Depression in children and adolescents has been found to be strongly associated with recurrent depression in adulthood and increase the risk for suicidal ideation, suicide attempts, and suicide completion. Among children and adolescents aged 8 to 15 years, 2% of boys and 4% of girls reported having MDD in the past year.

 

In a new guideline, the USPSTF recommended that primary care clinicians should screen adolescents aged 12 to 18 years for MDD. There has been adequate evidence found that screening tests could help detect depressive symptoms and lead to appropriate treatments. Adolescents who are screened and identified in primary care settings as having MDD and then treated have a reduction in symptoms and an improvement in daily functioning. In drafting the guideline, Dr. Siu, chairperson of the USPSTF, identified five studies on the accuracy of screening for MDD in primary care facilities and six studies on the efficacy of treatment. The authors noted there was no direct evidence of harm for screening in a primary care facility and the screenings had “reasonable accuracy” for picking up adolescents with MDD. When treatment is provided, the degree of harm resulting from antidepressant-related adverse events, psychotherapy, and collaborative care appeared to be beneficial and were not associated with significant harm.

 

The USPSTF recommend screening this age group when adequate systems are “in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up.” The recommendation grade of B was given which indicates there is moderate certainty that the net benefit is moderate to substantial.  There are several tools available for screening adolescents. The two most commonly studied are the Patient Health Questionnaire for Adolescents and the primary care version of the Beck Depression Inventory. The USPSTF opted not to issue any recommendation on screening for children aged 11 years and younger because of insufficient evidence. In addition, they note that more research is needed to better assess the effects of screening children on their health outcomes, the effect of comorbidities, the effectiveness of psychotherapy and combined-modality treatments, and the incidence of uncommon adverse events.

 

There are several risk factors that might help identify individuals who are at higher risk for developing symptoms of depression. These factors include, female gender, family (especially maternal) history of depression, prior episode of depression, other mental health or behavioral problems, chronic medical illness, overweight and obesity, and, in some studies, Hispanic race/ethnicity. Other psychosocial risk factors include childhood abuse or neglect, exposure to traumatic events (including natural disasters), loss of a loved one or romantic relationship, family conflict, uncertainty about sexual orientation, low socioeconomic status, and poor academic performance.

 

References:
London, S. (2016, February 9). USPSTF Recommends Depression Screening for Older Adolescents. Medscape. Retrieved from http://www.medscape.com/viewarticle/858653

 

Sui, A.L. (2016). Screening for Depression in Children and Adolescents: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine.

 

Jonathan Torres, M.S.
WKPIC Doctoral Intern

Friday Factoids Catch-Up: Optogenetics

 

Optogenetics involves tweaking the genes of neurons so that they become sensitive to light. By combining this technique with genetic and viral approaches, researchers can insert these channels into very specific populations of neurons. Ultimately, this approach allows researchers to control distinct groups of neurons and individual circuits of the brain by stimulating them with light-emitting devices inserted into the brain. First, researchers inject the subject with a genetically engineered virus, designed to infect brain tissue. These viruses aren’t harmful and have been engineered by scientists to deliver a benign DNA strand that code for special surface proteins, which respond to specific wavelengths of light. These single-celled organisms produce a protein called channelrhodopsin that makes them sensitive to sunlight.

 

At present, optogenetics can be used only on animals whose brain functions associated with elemental emotions, like fear and anxiety and reward, are similar to those in humans. Early tests have been successful in mice and primates to restore sight in blind test animals. Optogenetics was a major spur to the Obama Administration’s announcement, in 2013, of the BRAIN Initiative, a $300 million program for developing technologies to treat such neurological ailments as Alzheimer’s disease, autism, schizophrenia, and traumatic brain injury. It is possible that optogenetics could be used as a therapeutic tool in humans. Some clinicians are already looking at possible treatments in the peripheral nervous system

 

Optogenetics has given researchers unprecedented access to the workings of the brain, allowing them not only to observe its precise neural circuitry in lab animals but to control behavior through the direct manipulation of specific cells. The aim is to gain an understanding of brain functions such as attention, memory, social skills and emotions. For instance, a person diagnosed with schizophrenia displays cognitive impairment, which may hinder the performance of day-to-day tasks, such as showing up to work or the ability to make decisions. The challenge is to understand how the brain performs cognitive processes in the first place and how this is changed in psychiatric disorders. Several new studies have shown the potential of optogenetic stimulation to rapidly modify depression and anxiety related behaviors in animal models. It is potentially more effective and has fewer adverse effects than classic light therapy or pharmacological approaches to treat mental illness.

 

Circuit-level understanding of psychiatric symptoms is allowing more sophisticated pathophysiological hypotheses, which is important for replacing the current system of subjective report-based measures. Second, by combining patient interviews and personalized genomics, diagnoses of mental illnesses are well poised to change substantially in a manner that could improve both prevention and treatment. Third, direct knowledge of cells that are involved in psychiatric symptoms is facilitating identification of clinically relevant circuit biomarkers, which could revolutionize not only diagnosis but also prediction of treatment outcomes. It’s too early to say that optogenetics could inform the treatment in humans. But the research could enact changes on our models of mental illness.

 

References:
Albert, P.R. (2014). Light up your life: Optogenetics for depression? Journal of PsychiatryNeuroscience 39, 3-5.

 

Colapinto, J. (2015, May 18). Lighting the Brain. The New Yorker. Retrieved from http://www.newyorker.com/magazine/2015/05/18/lighting-the-brain

 

Myers, A. (2012, November 18). Optogenetics illuminates pathways of motivation through brain, study shows. Stanford Medicine. Retrieved from https://med.stanford.edu/news/all-news/2012/11/optogenetics-illuminates-pathways-of-motivation-through-brain-study-shows.html

 

Jonathan Torres, M.S.
WKPIC Doctoral Intern

 

[Director’s Note:  No, Dr. Greene, you may not go back to the rat lab just because this is interesting. Seriously. No.]